Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 113

1.

The heart failure pandemic: The clinical and economic burden in Greece.

Stafylas P, Farmakis D, Kourlaba G, Giamouzis G, Tsarouhas K, Maniadakis N, Parissis J.

Int J Cardiol. 2016 Oct 17. pii: S0167-5273(16)33013-3. doi: 10.1016/j.ijcard.2016.10.042. [Epub ahead of print]

PMID:
27915082
2.

Economic evaluation of trimetazidine in the management of chronic stable angina in Greece.

Kourlaba G, Gourzoulidis G, Andrikopoulos G, Tsioufis K, Beletsi A, Maniadakis N.

BMC Health Serv Res. 2016 Sep 27;16(1):520.

3.

The disease burden of chronic obstructive pulmonary disease in Greece.

Kourlaba G, Hillas G, Vassilakopoulos T, Maniadakis N.

Int J Chron Obstruct Pulmon Dis. 2016 Sep 9;11:2179-2189.

4.

A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients.

Kourlaba G, Gialama F, Tsioufis K, Maniadakis N.

Int J Cardiol. 2016 Oct 15;221:60-74. doi: 10.1016/j.ijcard.2016.06.115. Review.

PMID:
27404671
5.

Antibiotic prescribing and expenditures in outpatient adults in Greece, 2010 to 2013: evidence from real-world practice.

Kourlaba G, Gkrania-Klotsas E, Kourkouni E, Mavrogeorgos G, Zaoutis TE.

Euro Surveill. 2016 Jun 30;21(26). doi: 10.2807/1560-7917.ES.2016.21.26.30266.

6.

Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.

Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N.

Clin Drug Investig. 2016 Aug;36(8):649-59. doi: 10.1007/s40261-016-0410-2.

PMID:
27221806
7.

Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema.

Kourlaba G, Relakis J, Mahon R, Kalogeropoulou M, Pantelopoulou G, Kousidou O, Maniadakis N.

Cost Eff Resour Alloc. 2016 Apr 14;14:7. doi: 10.1186/s12962-016-0056-1.

8.

A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris.

Vellopoulou K, Kourlaba G, Maniadakis N, Vardas P.

Int J Cardiol. 2016 May 15;211:105-11. doi: 10.1016/j.ijcard.2016.02.140. Review.

PMID:
26994453
9.

Complications Related to Cardiac Rhythm Management Device Therapy and Their Financial Implication: A Prospective Single-Center TwoYear Survey.

Fanourgiakis J, Simantirakis E, Maniadakis N, Kanoupakis E, Chrysostomakis S, Kourlaba G, Chlouverakis G, Vardas P.

Hellenic J Cardiol. 2016 Jan-Feb;57(1):33-8.

10.

Perioperative antimicrobial prophylaxis in pediatric patients in Greece: Compliance with guidelines and impact of an educational intervention.

Dimopoulou A, Kourlaba G, Psarris A, Coffin S, Spoulou V, Zaoutis T.

J Pediatr Surg. 2016 Aug;51(8):1307-11. doi: 10.1016/j.jpedsurg.2015.11.017.

PMID:
26711690
11.

Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.

Kourlaba G, Vlachopoulos C, Parissis J, Kanakakis J, Gourzoulidis G, Maniadakis N.

BMC Health Serv Res. 2015 Dec 18;15:566. doi: 10.1186/s12913-015-1228-y.

12.

Cost-Utility Analysis of Certolizumab Pegol for the Treatment of Active Psoriatic Arthritis in GREECE.

Tzanetakos C, Vassilopoulos D, Kourlaba G, Christou P, Maniadakis N.

Value Health. 2015 Nov;18(7):A646-7. doi: 10.1016/j.jval.2015.09.2319. No abstract available.

13.

Cost-Utility of Certolizumab Pegol for The Treatment of Axial Spondyloarthritis In Greece.

Relakis I, Patrikos D, Kourlaba G, Christou P, Maniadakis N.

Value Health. 2015 Nov;18(7):A644. doi: 10.1016/j.jval.2015.09.2304. No abstract available.

14.

Budget Impact Analysis of Certolizumab Pegol In The Treatment of Axial Spondyloarthritis In Greece.

Relakis I, Patrikos D, Kourlaba G, Christou P, Maniadakis N.

Value Health. 2015 Nov;18(7):A639. doi: 10.1016/j.jval.2015.09.2277. No abstract available.

15.

Budget Impact Analysis of Certolizumab Pegol for The Treatment of Active Psoriatic Arthritis In Greece.

Tzanetakos C, Vassilopoulos D, Kourlaba G, Christou P, Maniadakis N.

Value Health. 2015 Nov;18(7):A638-9. doi: 10.1016/j.jval.2015.09.2274. No abstract available.

16.

Cost-Effectiveness of Dapagliflozin as Add-on to Metformin for the Treatment of Type 2 Diabetes in Greece.

Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N.

Value Health. 2015 Nov;18(7):A606-7. doi: 10.1016/j.jval.2015.09.2094. No abstract available.

17.

Cost-Effectiveness Analysis Of Granulocyte Colony-Stimulating Factors For The Prophylaxis Of Chemotherapy-Induced Febrile Neutropenia In Patients With Non-Hodgkin's Lymphoma In Greece.

Gourzoulidis G, Kourlaba G, Apostolidis J, Lyman GH, Villa G, Papagiannopoulou V, Tritaki G, Maniadakis N.

Value Health. 2015 Nov;18(7):A457. doi: 10.1016/j.jval.2015.09.1173. No abstract available.

18.

Cost-Effectiveness Analysis Of Granulocyte Colony-Stimulating Factors For The Prophylaxis Of Chemotherapy-Induced Febrile Neutropenia In Patients With Breast Cancer In Greece.

Kourlaba G, Gourzoulidis G, Aravantinos G, Athanasiadis I, Lyman GH, Villa G, Papagiannopoulou V, Tritaki G, Maniadakis N.

Value Health. 2015 Nov;18(7):A456. doi: 10.1016/j.jval.2015.09.1166. No abstract available.

19.

Health And Economic Outcomes Related to Delay Between Medical Indication and Treatment With Ranibizumab In Age-Related Macular Degeneration In Greece.

Kourlaba G, Chatzikou M, Pantelopoulou G, Maniadakis N.

Value Health. 2015 Nov;18(7):A423. doi: 10.1016/j.jval.2015.09.570. No abstract available.

20.

Cost-Utility of Ranibizumab Versus Aflibercept for Treating Visual Impairment Due to Diabetic Macular Edema In Greece.

Kourlaba G, Relakis J, Mahon R, Kalogeropoulou M, Pantelopoulou G, Kousidou O, Maniadakis N.

Value Health. 2015 Nov;18(7):A423. doi: 10.1016/j.jval.2015.09.568. No abstract available.

Items per page

Supplemental Content

Loading ...
Support Center